Reporter brief
Compounded and generic rapamycin showed different bioavailability in older adults in retrospective analysis.
What happened
A retrospective study compared blood rapamycin levels achieved with compounded versus generic formulations in older adults. The study aimed to determine the relative bioavailability ratio between the two formulations and their relative efficacy in raising rapamycin levels. The specific findings regarding bioavailability differences were not stated in the provided abstract.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Observational; Human.
normative aging individuals
- Design
- Observational
- Sample
- —
- Journal
- AgelessRx
- Published
- Aug 13, 2024
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.